Atara Biotherapeutics Inc at Jefferies Healthcare Conference Transcript
Good morning, everyone. My name is David Dai; I'm the Acting Research Associate here at Jefferies.
It's my pleasure to welcome Utpal Koppikar from Atara; he is the CFO of Atara. We're really excited to hear what his plans are for Atara.
Utpal?
Good morning. Thanks, David. I'm Utpal Koppikar, the Chief Financial Officer of Atara. Thanks for giving me the opportunity to tell Atara Bio's story this morning. I'll be making some forward-looking comments, so I direct you to our SEC filings as well as our Web Site if you have any questions.
Great, thank you. So we have quite a few activities going on in Atara. We continue to accelerate Tab-Cel in Phase III for PTLD, post-transplant lymphoproliferative disease. We also are moving forward with our Phase Ib/2 study with Tab-Cel in combination Keytruda in Nasopharyngeal Carcinoma, NPC. Also, we're advancing our next-generation CAR-T mesothelin targeted CAR-T for solid tumors based on some really
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
